Agilent Agrees to Buy Proscia for $240M

In its October 13, 2026 announcement, Agilent Technologies said it had agreed to buy Philadelphia-based Proscia for $240M in cash at closing, with up to $30M more tied to future performance milestones. Proscia’s trailing twelve-month revenue exceeded $18M: the upfront price is more than 13 times that disclosed floor, although the ratio to actual revenue remains unknown.

The agreement would bring Proscia’s digital pathology software into Agilent’s instruments and reagents business. A Reuters report says the companies expect to close the transaction early in Agilent’s fiscal 2027. Until the closing conditions are met, the $240M remains an agreed payment at closing, while the additional $30M depends on later performance.

What the revenue figure can establish

Dividing the $240M closing payment by $18M produces 13.33. That is a simple price-to-revenue comparison against the published revenue floor, not a verified multiple on Proscia’s actual sales. Because revenue was above that floor, the actual ratio must be below 13.33. It would still exceed 13 only if trailing revenue were below roughly $18.46M; the disclosed figure does not show whether that is the case.

The distinction is consequential for anyone comparing this purchase with other software deals. A rounded $18M denominator makes the transaction appear to carry a precise 13.3-times sales price, even though the denominator is expressly a minimum. The announced cash consideration also does not, by itself, provide the balance-sheet information needed to calculate a formal enterprise-value-to-revenue multiple. The available figures support a bounded comparison, rather than a precise transaction multiple.

How the earnout changes the potential price

If all performance milestones are achieved, cash consideration could reach $270M. Dividing that maximum by the same $18M revenue floor yields 15 times sales, again as a ceiling for a simple comparison using that floor. The potential increase reflects a separate, conditional payment; it does not change the $240M amount specified for closing.

The announced terms do not identify the milestones, their measurement period or how much each one would pay. That leaves the eventual acquisition cost dependent on Proscia’s performance after the agreement. For now, the useful distinction is between cash Agilent has agreed to pay when the deal closes and the additional amount that could become payable if the undisclosed targets are met.

What Agilent would acquire

Proscia’s Concentriq platform manages digital pathology images, data and workflows. It connects slide scanners, laboratory information systems, image-analysis applications and AI tools across clinical and life-sciences settings. For Agilent, ownership would put software that organizes pathology information alongside its existing instruments and reagents, giving the company a broader role in the work that follows the preparation and scanning of tissue slides.

According to MedTech Dive, Proscia serves more than 4,000 laboratories, hospitals and clinics, as well as 16 of the world’s top 20 pharmaceutical companies. Those figures describe the reach of the platform, not the amount those customers spend or the profitability of their contracts. Agilent’s interest in a recurring-revenue software business therefore sits beside a customer footprint spanning diagnostic laboratories and pharmaceutical research.

The proposed combination also connects different parts of a pathology workflow. Agilent supplies products used to prepare and analyze tissue; Proscia supplies software for handling the resulting digital images and associated data. Bringing those capabilities under one owner could make them easier to offer together, although the commercial benefit will depend on execution after closing.

An existing partnership becomes a proposed purchase

Fierce Biotech’s deal coverage traces the relationship to a September 2022 multiyear distribution agreement for a digital diagnostic pathology system. Agilent has therefore already had a route to sell an offering involving Proscia’s technology. The acquisition would turn that commercial relationship into direct ownership of the software provider and its wider platform.

In his October 13 post, Proscia CEO David West wrote, “Proscia brings software speed, product velocity, and AI; Agilent brings the scale and scientific infrastructure to amplify it.” His account describes why Proscia’s leadership favors the combination, rather than a quantified forecast of what the companies will earn together. It also points to the established partnership as a reason the teams know each other’s products and customers.

Proscia is expected to join Agilent’s Life Sciences and Diagnostics Markets Group if the transaction closes. The next decisive event is completion of the deal under its closing conditions; only then would the agreed cash payment become a completed purchase. Any later payment will turn on the performance milestones, whose results have yet to be determined.